pancreatic cancer

[Precigen, Inc.] Precigen, Inc. announced that the US FDA has cleared the Investigational New Drug (IND) application to initiate the Phase I/Ib clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) hematological and solid tumors.

[GenFleet Therapeutics] GenFleet Therapeutics announced the first patient with metastatic sigmoid adenocarcinoma has been dosed in a Phase Ib/II trial of GFH018 in combination with toripalimab as part of global multi-center clinical research. There are broad indications for GFH018 in treating solid tumors with lower response rates to PD-1 inhibitors.

[Aaps Pharmscitech] Therapeutic efficacy of antineoplastic agents possessing a selective target to the nucleus of the cancer cells could be enhanced through novel formulation approaches. Scientists showed that optimized formula enhanced cytotoxicity and apoptotic potential, compared with icariin (ICA)-raw, against pancreatic cancer cell lines.

[Advanced Materials] Investigators developed an enzyme activatied aggregation-induced emission probe QM-HSP-CPP for high-contrast fluorescence diagnosis of pancreatic cancer by monitoring specific overexpressed enzyme Cathepsin E.

[Journal of Biological Chemistry] Investigtors established a system-wide profile of the KRAS-regulated kinase signaling network in KRAS-mutant pancreatic ductal adenocarcinoma.

[Oncogene] Using several in vitro and in vivo models lacking C1GALT1 expression, investigators identified the role of aberrant O-glycosylation in stemness properties and aggressive pancreatic cancer metastasis.